May 27, 2015
During a 3-year period, costs for treating infants with neonatal abstinence syndrome increased from $1.1 million to $1.8 million annually, according to a study recently published in the Journal of Addiction Medicine.
Researchers from the University of Florida performed a retrospective chart review to calculate hospitalization costs related to neonatal abstinence syndrome (NAS) from December 2008 through November 2011. Eighty-six patients in the cohort (n = 160) showed in utero exposure to methadone, and nine were exposed to buprenorphine during pregnancy to manage maternal opioid addiction. Forty-nine patients also tested positive to short-acting opioids. Nine others were exposed to substances that included cocaine, marijuana or alprazolam.